Checks fatty liver risk in people with type 2 diabetes in routine care
Follows adults with type 2 diabetes treated with dapagliflozin and pioglitazone.
Plain-language title generated from the registry record
Registry title: A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Key facts
- Where
- Andong and Seoul, South KoreaSee the 2 sites
Where in South Korea
- Andong HospitalAndong, South KoreaTaking people
- Konkuk University Medical CenterSeoul, South KoreaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Trial code
- NCT06649162
- Record updated
- 18 October 2024
- Original description
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapyRead full original descriptionShow less
A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Inclusion: Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1); Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.
Exclusion: Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1); Those who are expected to need insulin prescription during the study period.